Stephen Holman is an Associate Principal Scientist at AstraZeneca. In this role he leads global mass spectrometry activities for late-stage drug development, specifically relating to the active pharmaceutical ingredient. Prior to joining AstraZeneca in 2018, Stephen was awarded his Ph.D in 2010 from the University of Southampton under the supervision of Professor John Langley, spent over eight years as a post-doctoral research associate at the universities of Manchester and Liverpool, and worked for Waters as a senior applications chemist specialising in biopharmaceuticals. Stephen was elected to the committee in 2010, and in 2013 assumed the role of Honorary Assistant Secretary.